Glenmark Pharmaceuticals, a Mumbai-based company, has announced the launch of its generic version of Epinephrine injection multiple-dose vial in the US market. This product is eligible for 180 days of competitive generic therapy (CGT) exclusivity. The injection is used to treat severe allergic reactions, including anaphylaxis, and to increase mean arterial blood pressure in adult patients with septic shock. The product is bioequivalent and therapeutically equivalent to the reference-listed drug from BPI Labs, LLC.
According to Glenmark’s President and Business Head, Marc Kikuchi, the launch of this injection grows the company’s portfolio of products within the institutional channel and reinforces its commitment to providing quality and affordable alternatives for patients. The company’s product, Glenmark’s Epinephrine injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial, is priced competitively, with the Epinephrine injection 10 mg/10 mL (1 mg/mL) market achieving annual sales of approximately $42.7 million, according to IQVIA sales data for the 12-month period ending December 2024.
The company’s new product is expected to benefit patients by providing a more affordable and accessible alternative to the branded product. The 180-day exclusivity period ensures that Glenmark’s product will not face competition from other generic versions of the medication for at least six months, which will give it a competitive edge in the market. Overall, the launch of Glenmark’s Epinephrine injection is a significant milestone for the company, demonstrating its ability to bring affordable and effective treatments to patients in the US market.